Johnson & Johnson $JNJ Stake Trimmed by Park National Corp OH

Key Points

• Park National Corp OH reduced its Johnson & Johnson stake by 4.8% in the third quarter, selling 6,117 shares and retaining 121,291 shares valued at approximately $32.1 million. Institutional investors collectively own 69.55% of J&J.
• Analysts maintain a positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $275.87; several firms recently raised their targets to as high as $300.
• J&J reported quarterly adjusted earnings of $2.90 per share and revenue of $25.31 billion, both above expectations. The company also pays a quarterly dividend of $1.34, equivalent to a 2.1% yield.

Park National Corp OH lowered its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 121,291 shares of the company's stock after selling 6,117 shares during the period. Park National Corp OH's holdings in Johnson & Johnson were worth $32,111,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Baker Tilly Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 4.7% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 10,423 shares of the company's stock worth $2,759,000 after acquiring an additional 469 shares during the last quarter. Ferguson Wellman Capital Management Inc. boosted its stake in shares of Johnson & Johnson by 41.0% during the third quarter. Ferguson Wellman Capital Management Inc. now owns 666,675 shares of the company's stock valued at $176,495,000 after purchasing an additional 193,905 shares during the period. Adelphi Trust Co increased its stake in Johnson & Johnson by 5.1% in the 3rd quarter. Adelphi Trust Co now owns 1,950 shares of the company's stock worth $516,000 after buying an additional 95 shares during the period. Eastern Bank lifted its holdings in Johnson & Johnson by 105.9% during the 3rd quarter. Eastern Bank now owns 299,306 shares of the company's stock valued at $79,238,000 after buying an additional 153,938 shares in the last quarter. Finally, Polaris Financial Partners bought a new position in Johnson & Johnson in the 3rd quarter worth about $56,000. Institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on JNJ shares. Johnson Rice reiterated a "buy" rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a report on Wednesday, July 15th. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. TD Cowen raised their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $275.87.

Johnson & Johnson Stock Down 0.7%

JNJ stock traded down $1.76 during trading on Monday, reaching $254.27. 3,866,893 shares of the company traded hands, compared to its average volume of 7,974,388. The business has a 50 day simple moving average of $266.37 and a 200 day simple moving average of $248.40. Johnson & Johnson has a 12 month low of $182.94 and a 12 month high of $281.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The company has a market capitalization of $612.77 billion, a price-to-earnings ratio of 29.45, a price-to-earnings-growth ratio of 2.52 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same period in the prior year, the firm posted $2.77 earnings per share. The company's quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.54 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is 62.11%.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 87,569 shares of company stock valued at $23,064,544 over the last three months. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.